GENEURO SA Press release
Availability of documents and information
for the annual shareholders' meeting of May 27, 2021
Geneva, Switzerland, May 6, 2021 - 6:00pm CEST - GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri,1228 Plan-les-Ouates, Geneva, Switzerland.
Based on article 27 of Ordinance 3 on Measures to combat the Coronavirus of 19 June 2020 (COVID- 19 Ordinance 3, status as of May 1st, 2021), the Board of Directors has decided that shareholders of the Company may exercise their rights at this Ordinary General Meeting exclusively through the Independent Proxy. This measure allows the Company to hold the Ordinary General Meeting as planned despite the pandemic. The conduct of the Ordinary General Meeting remains subject to additional measures issued by the Swiss authorities.
The notice for the meeting, including the agenda of the day as well as the motions put to the vote, has been published today in the Feuille Officielle Suisse du Commerce.
The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: www.geneuro.com, under the section Investors / Documentation / Shareholders meeting.
It is also possible to consult the documents at the Company's headquarters, chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates. Each shareholder has the right to request a hard copy of those documents.
About GeNeuro
GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
Contacts: | |||
GeNeuro | NewCap (France) | Halsin Partners | LifeSci Advisors |
Jesús Martin-Garcia | Louis-Victor Delouvrier / | Mike Sinclair (media) | Chris Maggos (investors) |
Mathilde Bohin (investors) | |||
Chairman and CEO | +33 1 44 71 98 52 | +44 20 7318 2955 | +41 79 367 6254 |
+41 22 552 48 00 | Arthur Rouillé (media) | msinclair@halsin.com | chris@lifesciadvisors.com |
investors@geneuro.com | +33 1 44 71 00 15 | ||
geneuro@newcap.eu |
1
Attachments
- Original document
- Permalink
Disclaimer
GeNeuro SA published this content on 06 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2021 21:58:07 UTC.
